Skip to main content
. 2011 Nov 1;15(9):2407–2424. doi: 10.1089/ars.2010.3751

FIG. 1.

FIG. 1.

Effect of in vivo tunicamycin (TN) challenge (1 or 3 mg/kg, i.p. for 48 h) on echocardiographic and cardiomyocyte contractile properties from wild-type (WT) and MyAkt mice. (A) Left ventricular end-systolic diameter (LVESD) using echocardiography; (B) left ventricular end-diastolic diameter (LVEDD) using echocardiography; (C) fractional shortening using echocardiography; (D) peak shortening (PS) (% of cell length) in cardiomyocytes; (E) maximal velocity of shortening (+dL/dt); (F) maximal velocity of relengthening (−dL/dt); (G) time-to-peak shortening (TPS); and (H) time-to-90% relengthening (TR90). Mean±SEM, n=6–7 mice and 86–87 cells for panels (A–C) and panels (D–H), respectively, *p<0.05 versus WT group; #p<0.05 versus respective WT-TN group.